| Literature DB >> 26801674 |
Hao Zhan1, Jiahao Jiang2, Chubin Luo1, Qiman Sun1,3, Aiwu Ke1, Chao Sun1, Jinwu Hu1, Zhiqiang Hu1, Bo Hu1, Kai Zhu1, Jia Fan1,3, Jian Zhou1,3, Xiaowu Huang4,5.
Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality and carries a dismal prognosis. The present study aimed to identify the tumour-suppressive role and clinical implications of PTPN13 in HCC progression. We tested the effects of PTPN13 expression in proliferation, invasion, epithelial-mesenchymal transition and associated pathways in HCC cell lines in vitro. Furthermore, its clinical relevance was evaluated in a tissue microarray analysis of samples from 282 HCC patients. Various HCC cell lines expressed relatively low PTPN13 protein levels in vitro. PTPN13 overexpression significantly inhibited the progression of HCC cells, possibly by inhibiting epithelial-mesenchymal transition through inactivation of the EGFR/ERK signalling pathway. Tissue microarray analysis revealed that high PTPN13 expression was correlated with a favourable prognosis in postoperative HCC patients. This study demonstrated the tumour suppressor, PTPN13, as an alternative therapeutic target for HCC.Entities:
Keywords: Epithelial–mesenchymal transition; Hepatocellular carcinoma; Metastasis; Non-receptor type 13 (PTPN13); Prognosis; Protein tyrosine phosphatases
Mesh：
Substances：
Year: 2016 PMID： 26801674 DOI： 10.1007/s13277-016-4843-2
Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283